NEUROCRINE BIOSCIENCES INC Research and Development in Process
NEUROCRINE BIOSCIENCES INC (NBIX) reported Research and Development in Process of $5.00 million for the 3-month period ending 2019-06-30, per its 10-Q filed 2019-07-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2019-07-29
- NEUROCRINE BIOSCIENCES INC research and development in process for the quarter ending 2019-06-30 was $5.00M.
- NEUROCRINE BIOSCIENCES INC research and development in process for the quarter ending 2019-03-31 was $113.08M.
| Period end | Research and Development in Process 3 month | Research and Development in Process 6 month |
|---|---|---|
| 2019-06-30 | $5.00M 10-Q · filed 2019-07-29 | $118.08M 10-Q · filed 2019-07-29 |
| 2019-03-31 | $113.08M 10-Q · filed 2019-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |